Insurtech: The Price of Growth - A Cash vs. Love Story

Hippo's Market Entry and Initial Trading Performance

Trading of Hippo shares commenced earlier this week following the completion of its merger with a Special Purpose Acquisition Company (SPAC). Initially, the stock price remained near the pre-combination level of $10 per share.

However, a significant decline occurred yesterday during standard trading hours. This downturn doesn't seem to stem from company-specific issues.

The Impact of Lemonade's Earnings Report

Lemonade, a fellow U.S. neoinsurance provider specializing in rental insurance, released its Q2 results earlier in the week, which were marginally better than anticipated.

Following the report, Lemonade experienced a substantial drop in its valuation, and this appears to have negatively impacted Hippo’s stock as well.

The Exchange provides insights into startups, markets, and financial matters.

Access it daily on Extra Crunch or subscribe to The Exchange newsletter every Saturday.

A Broader Trend in Neoinsurance Valuations

The observed trading volatility is noteworthy, but the more crucial aspect is the broader decline in valuations across several neoinsurance companies.

This week’s decreases aren’t unexpected; the market has been reassessing tech-enabled insurance providers in recent quarters, a shift from the previous positive investor sentiment.

Analyzing Public and Private Market Dynamics

Typically, we would analyze the new valuations of publicly traded neoinsurance companies to infer potential implications for private startups.

Utilizing public market data to understand private market trends is a common practice in this column.

Cash-Rich, Sentiment-Poor Companies

Today, we will focus on an intriguing dynamic within the neoinsurance sector that may be particularly relevant to understanding the private markets.

The publicly traded companies in this space generally possess substantial cash reserves but are facing negative market sentiment.

Enterprise Value vs. Market Capitalization

While public markets are reducing the value of neoinsurance stocks, the underlying companies maintain significant wealth.

This results in enterprise values that may be lower than suggested by their market capitalization alone. The question arises: do Lemonade or Hippo significantly concern themselves with short-term stock market fluctuations?

Do they have sufficient financial resources to pursue their long-term strategies irrespective of market perceptions?

Examining the Financials and Leadership Perspectives

Let's delve into the financial data, discuss an interview The Exchange conducted with Hippo CEO Assaf Wand earlier this week, and review Lemonade’s statements during its earnings call.

Navigating Choppy Waters

It’s certainly not ideal for neoinsurance startups that their public counterparts are experiencing market turbulence.

However, for the public companies themselves, this may be an opportune moment to remain steadfast in their plans and disregard the concerns of financial analysts.

Significant Capital Reserves Amidst Market Correction

Lemonade’s initial public offering in July 2020 generated substantial gains and paved the way for subsequent public debuts of new insurance companies. Root followed suit with its public listing in October of the same year. MetroMile announced a special purpose acquisition company (SPAC) merger in November 2020, while Hippo revealed its own SPAC agreement in March 2021.

It’s important to note that Lemonade primarily concentrates on renters insurance, with a broadening range of offerings. Conversely, both Root and MetroMile specialize in auto insurance policies. Hippo’s core business revolves around homeowners insurance, although they are actively diversifying their product portfolio over time.

The following data illustrates the current standing of these four companies in relation to their 52-week high valuations, calculated based on yesterday’s closing prices:

• Lemonade: -57%
• Root: -76%
• MetroMile: -66%
• Hippo: -47%

The reported decline for Hippo is somewhat misleading, as its peak valuation occurred earlier in the year when SPACs were trading at premiums above their initial public offering price. A more accurate assessment indicates Hippo is down 20% from its merger price.

Despite this, the overall performance remains considerably unfavorable. Investors are potentially reassessing the anticipated growth rates of these neoinsurance firms, or perhaps anticipating a longer timeframe for revenue quality to improve, or a combination of both. This doesn't reflect positively on the individual companies, nor their combined efforts to modernize the insurance sector through technology and user-friendly applications.

Let's examine the companies’ most recent cash reserves and, where available, their operating cash burn from the latest quarter:

• Lemonade: $1.2 billion in cash and equivalents, $56.5 million operating cash burn in Q2 [source]
• Root: $1.1 billion in cash and equivalents, $90.9 million operating cash burn in Q1 [source]
• MetroMile: $221.5 million in cash and equivalents, $29.4 million operating cash burn in Q1 [source]
• Hippo: Approximately $1 billion in cash, $15.5 million operating cash burn in Q1 [source]

This indicates Lemonade possesses over five years of cash runway at its current burn rate. Root has approximately three years of funding available. MetroMile has just under two years. Hippo, meanwhile, appears well-capitalized for the foreseeable future, although its figures required some compilation and will be clarified upon earnings release.

The substantial cash positions held by these companies suggest they secured funding at opportune moments, capitalizing on the positive market response to Lemonade’s successful public debut. While current market sentiment regarding their economic viability is less optimistic, they have already secured the necessary capital.

Consequently, these companies must now prioritize the strategies that all publicly traded firms claim to pursue: concentrate on future development and aggressively expand their operations.

Hippo

Even prior to recent market events causing Lemonade to experience a significant decrease in value – exceeding ten percent – this article was scheduled for release. Previously, in late July, we questioned whether insurtech valuations warranted concern. The answer, it appears, was affirmative.

However, according to Hippo’s CEO, the recent shifts in the market are not the primary issue. The complexities surrounding its SPAC merger, specifically the lower-than-anticipated capital raised, are not considered a substantial setback, as reported by Wand.

The CEO stated that Hippo will maintain approximately $1 billion in reserves following the merger, expressed in rounded figures. The difference between this amount and the initially projected $1.1 billion is deemed inconsequential.

His argument centers on the construction of a durable, long-term enterprise, rendering short-term market volatility less critical. He believes superior technology and a dedication to customer satisfaction will ultimately prevail.

Essentially, he possesses substantial financial resources, providing ample time, and his core vision for the company remains unchanged.

This perspective mirrors the sentiments expressed by Root CEO Alex Timm following his company’s Q1 2021 earnings report. Timm emphasized a long-term focus, suggesting the market may not fully grasp Root’s future growth potential.

Timm also conveyed optimism regarding the technology driving his insurance company, highlighting its ability to refine pricing strategies and enhance accuracy over time. He, too, prioritizes future expansion and sustained value creation.

These statements closely resemble the tone of Lemonade’s recent earnings call, particularly the CEO’s opening remarks.

The central question remains: who is more accurate – the CEOs or the market? The answer is currently unknown. However, it is evident that these CEOs successfully attracted investment when market conditions were favorable.

Now, they have considerable time to demonstrate the validity of their strategies and the long-term viability of their companies.

Several privately held neoinsurance companies are closely monitoring the performance of their publicly traded counterparts, hoping for a recovery in their market value. However, a return to previous levels of investor enthusiasm may take time.

Ultimately, success hinges on the effectiveness of their business models and the strategic utilization of their financial reserves.

Time will tell.